F. Bach

964 total citations
25 papers, 632 citations indexed

About

F. Bach is a scholar working on Genetics, Oncology and Neurology. According to data from OpenAlex, F. Bach has authored 25 papers receiving a total of 632 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 10 papers in Oncology and 8 papers in Neurology. Recurrent topics in F. Bach's work include Glioma Diagnosis and Treatment (15 papers), Neuroblastoma Research and Treatments (8 papers) and Cancer, Hypoxia, and Metabolism (6 papers). F. Bach is often cited by papers focused on Glioma Diagnosis and Treatment (15 papers), Neuroblastoma Research and Treatments (8 papers) and Cancer, Hypoxia, and Metabolism (6 papers). F. Bach collaborates with scholars based in Germany, Italy and Cuba. F. Bach's co-authors include Manfred Westphal, Dirk Reuter, J. H. Williams, Sidney R. Kushner, U. Bode, Gudrun Fleischhack, Torsten Pietsch, Maura Massimino, Joachim P. Steinbach and Uwe Schlegel and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Clinical Oncology and European Journal of Cancer.

In The Last Decade

F. Bach

24 papers receiving 612 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
F. Bach Germany 13 292 196 164 136 99 25 632
Do Hyun Nam South Korea 14 243 0.8× 175 0.9× 193 1.2× 209 1.5× 125 1.3× 34 725
M Brampton United Kingdom 6 199 0.7× 250 1.3× 329 2.0× 181 1.3× 39 0.4× 8 785
Cédric Mercier France 18 181 0.6× 569 2.9× 391 2.4× 196 1.4× 47 0.5× 49 991
R. L. Stone United States 2 153 0.5× 115 0.6× 158 1.0× 110 0.8× 33 0.3× 3 347
Mickaël Bourgeois France 22 67 0.2× 319 1.6× 189 1.2× 200 1.5× 67 0.7× 45 996
Anlai Wang United States 12 103 0.4× 228 1.2× 330 2.0× 40 0.3× 12 0.1× 40 958
Rajesh R. Nair United States 17 178 0.6× 239 1.2× 385 2.3× 63 0.5× 12 0.1× 42 861
G. Guetens Belgium 13 77 0.3× 291 1.5× 265 1.6× 154 1.1× 17 0.2× 23 658
Peter Drückes Switzerland 9 78 0.3× 240 1.2× 262 1.6× 40 0.3× 24 0.2× 9 596

Countries citing papers authored by F. Bach

Since Specialization
Citations

This map shows the geographic impact of F. Bach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Bach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Bach more than expected).

Fields of papers citing papers by F. Bach

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Bach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Bach. The network helps show where F. Bach may publish in the future.

Co-authorship network of co-authors of F. Bach

This figure shows the co-authorship network connecting the top 25 collaborators of F. Bach. A scholar is included among the top collaborators of F. Bach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Bach. F. Bach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fleischhack, Gudrun, Maura Massimino, Monika Warmuth‐Metz, et al.. (2019). Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study. Journal of Neuro-Oncology. 143(1). 107–113. 30 indexed citations
2.
Westphal, Manfred, Oliver Heese, Joachim P. Steinbach, et al.. (2015). A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma. European Journal of Cancer. 51(4). 522–532. 156 indexed citations
3.
Massimino, Maura, Veronica Biassoni, Rosalba Miceli, et al.. (2014). O10.10 * RESULTS OF NIMOTUZUMAB AND VINORELBINE, RADIATION AND RE-IRRADIATION FOR DIFFUSE PONTINE GLIOMA IN CHILDHOOD. Neuro-Oncology. 16(suppl 2). ii25–ii25. 3 indexed citations
4.
5.
Strumberg, Dirk, Beate Schultheis, Matthias Ebert, et al.. (2013). Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC).. Journal of Clinical Oncology. 31(15_suppl). 4009–4009. 13 indexed citations
6.
Bode, U., Maura Massimino, F. Bach, et al.. (2012). Nimotuzumab treatment of malignant gliomas. Expert Opinion on Biological Therapy. 12(12). 1649–1659. 45 indexed citations
7.
Alert, José, et al.. (2012). Radiotherapy plus the anti-EGFR mAb nimotuzumab or placebo for the treatment of high-grade glioma patients.. Journal of Clinical Oncology. 30(15_suppl). 2515–2515. 2 indexed citations
8.
9.
Bach, F., et al.. (2011). Current status of a phase III trial of nimotuzumab (ti-EGF-R) in newly diagnosed glioblastoma.. Journal of Clinical Oncology. 29(15_suppl). 2059–2059. 3 indexed citations
10.
Strumberg, Dirk, Beate Schultheis, M. E. Scheulen, et al.. (2010). Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. International Journal of Clinical Pharmacology and Therapeutics. 48(7). 473–475. 12 indexed citations
11.
Strumberg, Dirk, Beate Schultheis, M. E. Scheulen, et al.. (2010). Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Investigational New Drugs. 30(3). 1138–1143. 55 indexed citations
12.
13.
Ehrhart, Friederike, Julia Schulz, Alisa Katsen‐Globa, et al.. (2008). A comparative study of freezing single cells and spheroids: Towards a new model system for optimizing freezing protocols for cryobanking of human tumours. Cryobiology. 58(2). 119–127. 24 indexed citations
14.
Bode, U., Maura Massimino, M. Warmuth-Metz, et al.. (2008). Phase III trial of nimotuzumab for the treatment of newly diagnosed diffuse intrinsic pontine gliomas in children and adolescents. Journal of Clinical Oncology. 26(15_suppl). 2058–2058. 13 indexed citations
15.
Bode, U., et al.. (2007). Final report of a phase II trial of nimotuzumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents. Journal of Clinical Oncology. 25(18_suppl). 2006–2006. 25 indexed citations
16.
Bode, U., et al.. (2006). Results of a phase II trial of h-R3 monoclonal antibody (nimotuzumab) in the treatment of resistant or relapsed high-grade gliomas in children and adolescents. Journal of Clinical Oncology. 24(18_suppl). 1522–1522. 12 indexed citations
17.
Bach, F., Niels Agerlin, Jens Benn Sørensen, et al.. (1996). [Metastatic spinal cord compression in patients with lung cancer].. PubMed. 158(40). 5606–10.
18.
Gersing, E., et al.. (1991). Messung der elektrischen Impedanz von Organen — Methodische Grundlagen - Measurement of Electrical Impedance in Organs – Fundamentals and Methodology. Biomedizinische Technik/Biomedical Engineering. 36(4). 70–77. 13 indexed citations
19.
Bach, F., Herbert J. Brabander, & Steven A. Kushner. (1957). Vasodilator and Adrenergic Blocking Agents. I. 1,4-Disubstituted Piperazines and Related N-Phenylethylenediamine Derivatives. Journal of the American Chemical Society. 79(9). 2221–2225. 10 indexed citations
20.
Kushner, Sidney R., et al.. (1955). Experimental Chemotherapy of Tuberculosis. III. Ethyl Mercaptan and Related Compounds in Tuberculosis. Journal of the American Chemical Society. 77(5). 1152–1155. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Do Hyun Nam Breakdown of academic impact, for papers by M Brampton Breakdown of academic impact, for papers by Cédric Mercier Breakdown of academic impact, for papers by R. L. Stone Breakdown of academic impact, for papers by Mickaël Bourgeois Breakdown of academic impact, for papers by Anlai Wang Breakdown of academic impact, for papers by Rajesh R. Nair Breakdown of academic impact, for papers by G. Guetens Breakdown of academic impact, for papers by Peter Drückes
Rankless by CCL
2026